Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 24,939,948 Common Shares outstanding as of 03/24/2026 as reported by Pasithea Therapeutics Corp. on 03/31/2026, in its Form 10-K.


SCHEDULE 13G





SCHEDULE 13G



 
Opaleye Management Inc.
 
Signature:/s/ James Silverman
Name/Title:President
Date:04/08/2026
 
Opaleye, L.P.
 
Signature:/s/ James Silverman
Name/Title:General Partner
Date:04/08/2026
 
James Silverman
 
Signature:/s/ James Silverman
Name/Title:Individually
Date:04/08/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons